Investigating HIV-1 Resistance to CCR5 Antagonist Maraviroc for the Design of New Prevention Strategies

被引：0
|
作者：
Flynn, Jacqueline K. [1 ,2 ]
Roche, Michael [1 ,2 ]
Paukovics, Geza [1 ]
Salimi, Hamid [1 ,2 ]
Duncan, Renee C. [1 ]
Moore, Miranda S. [1 ]
Ellet, Anne [1 ]
Gray, Lachlan R. [1 ,2 ]
Jubb, Becky [3 ]
Westby, Mike [3 ]
Purcell, Damian F. J. [4 ]
Lewin, Sharon R. [1 ,2 ]
Lee, Benhur [5 ]
Payne, Richard J. [6 ]
Churchill, Melissa J. [1 ,2 ]
Gorry, Paul R. [1 ,2 ]
机构：
[1] Burnet Inst, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic 3004, Australia
[3] Pfizer Global Res & Dev, Sandwich, Kent, England
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Univ Sydney, Sydney, NSW 2006, Australia
来源：
AIDS RESEARCH AND HUMAN RETROVIRUSES | 2014年 / 30卷
关键词：
D O I：
10.1089/aid.2014.5459.abstract
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P35.02
引用
收藏
页码：A212 / A212
页数：1
相关论文
共 50 条
  • [1] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    [J]. FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [2] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
  • [3] Maraviroc: a new CCR5 antagonist
    Sayana, Shilpa
    Khanlou, Homayoon
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (01) : 9 - 19
  • [4] Treatment of HIV infection with the CCR5 antagonist maraviroc
    Kromdijk, Wiete
    Huitema, Alwin D. R.
    Mulder, Jan Willem
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1215 - 1223
  • [5] Maraviroc - The first CCR5 antagonist for the treatment of HIV
    Girotto, Jennifer E.
    [J]. FORMULARY, 2007, 42 (10) : 601 - 608
  • [6] Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Fätkenheuer, G
    Pozniak, AL
    Johnson, MA
    Plettenberg, A
    Staszewski, S
    Hoepelman, AIM
    Saag, MS
    Goebel, FD
    Rockstroh, JK
    Dezube, BJ
    Jenkins, TM
    Medhurst, C
    Sullivan, JF
    Ridgway, C
    Abel, S
    James, IT
    Youle, M
    van der Ryst, E
    [J]. NATURE MEDICINE, 2005, 11 (11) : 1170 - 1172
  • [7] Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Gerd Fätkenheuer
    Anton L Pozniak
    Margaret A Johnson
    Andreas Plettenberg
    Schlomo Staszewski
    Andy I M Hoepelman
    Michael S Saag
    Frank D Goebel
    Jürgen K Rockstroh
    Bruce J Dezube
    Tim M Jenkins
    Christine Medhurst
    John F Sullivan
    Caroline Ridgway
    Samantha Abel
    Ian T James
    Mike Youle
    Elna van der Ryst
    [J]. Nature Medicine, 2005, 11 : 1170 - 1172
  • [8] Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
    Yost, Raymond
    Pasquale, Timothy R.
    Sahloff, Eric G.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (08) : 715 - 726
  • [9] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Soulie, Cathia
    Malet, Isabelle
    Lambert-Niclot, Sidonie
    Tubiana, Roland
    Thevenin, Monique
    Simon, Anne
    Murphy, Robert
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    [J]. AIDS, 2008, 22 (16) : 2212 - 2214
  • [10] The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets
    Flynn, Jacqueline K.
    Paukovics, Geza
    Moore, Miranda S.
    Ellett, Anne
    Gray, Lachlan R.
    Duncan, Renee
    Salimi, Hamid
    Jubb, Becky
    Westby, Mike
    Purcell, Damian F. J.
    Lewin, Sharon R.
    Lee, Benhur
    Churchill, Melissa J.
    Gorry, Paul R.
    Roche, Michael
    [J]. VIROLOGY, 2013, 442 (01) : 51 - 58
12345